Psoriatic Arthritis
📧 Sign up to get email alerts when something new happens for Psoriatic Arthritis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-06-19Clinical Trial Update: Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Psoriasis)
Pfizer's infliximab biosimilar was studied in a Drug Use Investigation for psoriasis indications; the trial has completed and results were p…
-
CLINICAL_TRIALS research · 2025-06-19Clinical Trial Update: Evaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms
This clinical trial investigates whether interleukin-17 (IL-17) acts as an orchestrator between peripheral inflammation and depressive sympt…
-
CLINICAL_TRIALS trial_result · 2025-06-11Clinical Trial Update: The Risk of Venous Thromboembolism in Systemic Inflammatory Disorders: a United Kingdom (UK) Matched Cohort Study
Results from a UK matched-cohort study examine the risk of venous thromboembolism among people with systemic inflammatory disorders. The tri…
-
CLINICAL_TRIALS research · 2025-06-11Clinical Trial Update: Psorcast Mobile Study
The Psorcast Mobile Study sponsored by Sage Bionetworks is currently recruiting participants to study psoriatic arthritis and psoriasis.
-
CLINICAL_TRIALS trial_result · 2025-06-08Clinical Trial Update: Special Drug Use-results Survey to Evaluate Safety and Efficacy of Cosentyx in Pediatric Patients With PsV, PsA, or GPP
Special-use survey results assess the safety and efficacy of Cosentyx (secukinumab) in pediatric patients with psoriasis vulgaris, psoriatic…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-06-03Clinical Trial Update: Medical Follow-up of New Cases of Polyarthritis in Children and Young Adults
This clinical trial update notes ongoing recruitment for a longitudinal follow-up study of newly diagnosed polyarthritis in children and you…
-
CLINICAL_TRIALS research · 2025-05-23Clinical Trial Update: A Prospective Study to Assess the Efficacy of IL-17 Inhibitors on Subclinical Enthesitis in Patients With Moderate to Severe Psoriasis Based on Power Doppler (PD) Ultrasonography (PDUS)
This clinical trial is currently recruiting to evaluate whether IL-17 inhibitors (e.g., Secukinumab) reduce subclinical enthesitis in patien…
-
CLINICAL_TRIALS trial_result · 2025-05-23Clinical Trial Update: Psoriatic Arthritis Study of Izokibep [Phase 2, Phase 3]
ACELYRIN's Phase 2/3 trial of izokibep for psoriatic arthritis was terminated, and the results have been posted. Details on efficacy and saf…
-
FDA approval · 2025-05-22FDA Approved: STARJEMZA — Original Application (Hikma Pharmaceuticals USA Inc.)
FDA approved STARJEMZA (ustekinumab-hmny) from Hikma Pharmaceuticals USA Inc. as a biosimilar to ustekinumab, enabling marketing for the sam…
-
CLINICAL_TRIALS research · 2025-05-20Clinical Trial Update: Assessing Pain by the painDETECT Questionnaire (PDQ)
A clinical trial update describes a study using the painDETECT questionnaire to assess pain in inflammatory arthritis and related conditions…
-
EMA approval · 2025-05-19EMA Authorised: Orencia (abatacept) — Bristol-Myers Squibb Pharma EEIG
The EMA authorised Orencia (abatacept) by Bristol-Myers Squibb Pharma EEIG for rheumatoid arthritis, psoriatic arthritis, and juvenile idiop…
-
CLINICAL_TRIALS research · 2025-05-16Clinical Trial Update: Potential Role of Guselkumab in Modulating PAIN Perception and Related Gene Pathways: a Proof-of-concept Study. [Phase 4]
Phase 4 proof-of-concept study evaluating whether guselkumab can modulate pain perception and related gene pathways in psoriatic arthritis; …
-
CLINICAL_TRIALS trial_result · 2025-05-09Clinical Trial Update: Psoriatic Arthritis Research Collaborative: Biologic Sub-Study
A completed Biologic Sub-Study in the Psoriatic Arthritis Research Collaborative, sponsored by the University of Pennsylvania; results were …
-
CLINICAL_TRIALS trial_result · 2025-05-02Clinical Trial Update: COVID-19 VaccinE Response in Rheumatology Patients [Phase 4]
Phase 4 trial evaluating the COVID-19 vaccine response in patients with rheumatic diseases has completed, including rheumatoid arthritis, ps…
-
FDA approval · 2025-04-30FDA Approved: USTEKINUMAB-TTWE — Original Application (Quallent Pharmaceuticals Health LLC)
FDA approves an original biologics license application for USTEKINUMAB-TTWE from Quallent Pharmaceuticals Health LLC.
-
FDA approval · 2025-04-30FDA Approved: SELARSDI — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for SELARSDI (ustekinumab-aekn) from Teva Pharmaceuticals USA, Inc., representing an approval of a b…
-
FDA approval · 2025-04-30FDA Approved: OTULFI — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for OTULFI (ustekinumab-aauz) from Fresenius Kabi USA, LLC.
-
FDA approval · 2025-04-30FDA Approved: STEQEYMA — Original Application (CELLTRION USA, Inc.)
The FDA approved STEQEYMA (ustekinumab-stba) from Celltrion USA, Inc. under an Original Biologics License Application.
-
FDA approval · 2025-04-30FDA Approved: YESINTEK — Original Application (Biocon Biologics Inc.)
The FDA approved Yesintek (ustekinumab) from Biocon Biologics Inc. under an original Biologics License Application. It is indicated for plaq…
-
FDA approval · 2025-04-30FDA Approved: OTULFI — Original Application (Fresenius Kabi USA, LLC)
OTULFI (USTEKINUMAB-AAUZ) received FDA approval under an Original Application from Fresenius Kabi USA, LLC.
-
FDA approval · 2025-04-28FDA Approved: STEQEYMA — Supplemental Application (CELLTRION USA, Inc.)
The FDA approved a supplemental application for STEQEYMA (ustekinumab-stba) from Celltrion USA, Inc.
-
CLINICAL_TRIALS research · 2025-04-27Clinical Trial Update: Biologic Treatment Registry Across Canada
A completed Canadian registry study by Janssen documenting biologic treatments across inflammatory arthritis conditions, including rheumatoi…
-
FDA approval · 2025-04-14FDA Approved: OTULFI — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental Biologics License Application for OTULFI (ustekinumab-AAUZ) from Fresenius Kabi USA, LLC.
-
CLINICAL_TRIALS trial_result · 2025-04-13Clinical Trial Update: A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment [Phase 3]
A Phase 3 trial comparing deucravacitinib to placebo in active psoriatic arthritis patients (biologic-naïve or prior TNF inhibitor exposure)…
-
CLINICAL_TRIALS research · 2025-04-10Clinical Trial Update: AYLo - AutoimmunitY and Loss of y
Clinical trial AYLo from the University of Bonn investigates autoimmunity across multiple diseases and is currently recruiting.